Fiche publication
Date publication
janvier 2016
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie
Tous les auteurs :
Milleron B, Westeel V, Gounant V, Wislez M, Quoix E
Lien Pubmed
Résumé
The phase III trials of adjuvant and neoadjuvant chemotherapy showed a 5 % increase survival but the clinical research in this area is difficult because the duration of the trials with overall survival as primary end point is around 10years. To shorten the duration of these studies, the use of surrogate end points such as disease-free survival or relapse-free survival is possible, but does not significantly reduce the duration of studies. Several studies in and outside the lung cancer showed histological complete response or the percentage of viable tumor cells after chemotherapy could be correlated with survival and thus become an interesting alternative criterion. If this is verified, clinical studies of preoperative chemotherapy should be shortened which would allow patients faster access to innovative treatment in the perioperative situation.
Mots clés
Breast Neoplasms, drug therapy, Carcinoma, Non-Small-Cell Lung, drug therapy, Chemotherapy, Adjuvant, Clinical Trials as Topic, Disease-Free Survival, Female, Humans, Induction Chemotherapy, Lung Neoplasms, drug therapy, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Preoperative Care, Publishing, Rectal Neoplasms, drug therapy, Time Factors
Référence
Bull Cancer. 2016 Jan;103(1):66-72
